Cannabis and Gastroparesis
Cannabis is sometimes used for gastroparesis symptoms, but the evidence is thin and chronic use can paradoxically make gastric emptying worse.
Gastroparesis is miserable, treatments are limited, and patients understandably reach for cannabis. The honest picture: cannabinoids can blunt nausea and improve appetite in some people, but THC actually *slows* gastric emptying in healthy volunteers and in patients. So you may feel better while the underlying motility problem gets worse. Dronabinol has the most data, and it's modest. Anyone telling you cannabis 'treats' gastroparesis is overselling. Anyone telling you it's worthless for symptoms is also overselling. The truth is narrower and less satisfying than either claim.
Plain-language summary
Gastroparesis is delayed emptying of the stomach without a mechanical obstruction. Common causes are diabetes, post-surgical vagus nerve injury, and idiopathic (unknown). Symptoms include nausea, vomiting, early satiety, bloating, and upper abdominal pain. Standard treatments — dietary changes, metoclopramide, domperidone, erythromycin, and gastric electrical stimulation — help some patients and fail others, which is why many people try cannabis [1].
The core tension: cannabis (especially THC) reliably reduces nausea for many people Strong evidence but also slows gastric emptying in human studies Strong evidence [2][3]. That means it can mask symptoms while worsening the underlying motility defect, and with heavy chronic use it can trigger cannabinoid hyperemesis syndrome, which is easily mistaken for a gastroparesis flare [4].
This article is not medical advice. Gastroparesis can cause dangerous dehydration, malnutrition, and electrolyte disturbances. Decisions about cannabis use should involve your gastroenterologist, especially if you are diabetic, pregnant, on prokinetics, or have a history of cyclic vomiting.
What probably works
Honestly, nothing in cannabis has 'probably works' status for gastroparesis itself. No cannabinoid is FDA-approved for this indication, and there are no large randomized trials in gastroparesis patients specifically.
The strongest adjacent evidence is for cannabinoids as antiemetics, mostly from chemotherapy-induced nausea and vomiting (CINV). Dronabinol (synthetic THC) and nabilone are approved for CINV and have decades of trial data showing they reduce nausea and vomiting better than placebo and comparably to older antiemetics Strong evidence [5]. Whether that translates to gastroparesis nausea is an extrapolation, not a demonstrated fact.
A small retrospective study of dronabinol in gastroparesis patients reported symptom improvement in nausea and abdominal pain Weak / limited [6]. That's the closest thing to direct evidence, and it's a chart review, not a controlled trial.
What might work
- Low-dose THC or dronabinol for nausea episodes Weak / limited. Plausible mechanism (CB1 agonism in brainstem emetic centers), supported by CINV data, weak direct gastroparesis data.
- CBD for visceral pain and anxiety component Weak / limited. CBD has some preclinical anti-nausea signal and human anxiolytic data, but no gastroparesis-specific trials. The anxiety-nausea loop is real and treating one can help the other.
- Appetite stimulation Weak / limited. THC reliably increases appetite in HIV wasting and cancer cachexia trials [7]. Patients with early satiety sometimes report easier eating, though this is anecdotal in the gastroparesis context.
- Inhaled vs. oral routes: Inhaled cannabis has faster onset, which matters when you can't keep oral medications down. But inhalation doesn't avoid the motility-slowing effect, it just changes pharmacokinetics. Anecdote for the specific claim that inhalation is 'better for gastroparesis.'
What doesn't work or has weak evidence
- Cannabis as a prokinetic. It is the opposite of a prokinetic. THC delays gastric emptying in healthy volunteers and in patients with functional dyspepsia Strong evidence [2][3]. Claims that 'indica relaxes the stomach' or that cannabis 'heals' gastroparesis are folklore, not pharmacology.
- Terpene-based protocols (e.g., 'beta-caryophyllene strains for GI motility'). Interesting preclinical receptor biology, zero clinical evidence in gastroparesis. No data
- Strain-specific recommendations ("this indica is good for stomach issues"). The indica/sativa distinction does not reliably predict effects or chemistry [8]. Disputed
- CBD-only products as a gastroparesis treatment. No clinical trials. Sold heavily online for GI complaints. No data
What we don't know
- Whether long-term cannabinoid use changes the natural history of gastroparesis (better, worse, or neutral).
- Optimal dose, route, or cannabinoid ratio for symptom control without worsening motility.
- Whether CBD alone (without THC) helps gastroparesis symptoms at all.
- How to reliably distinguish a gastroparesis flare from early cannabinoid hyperemesis syndrome in a chronic user — this is a clinically important diagnostic problem with no clean answer [4].
- Whether cannabinoids interact meaningfully with prokinetics like metoclopramide or erythromycin.
There are no large randomized controlled trials of cannabis in gastroparesis. Until those exist, anything stronger than 'might help nausea, probably worsens emptying' is speculation.
Comparison with standard treatments
| Treatment | Evidence | Mechanism | Key risks | |---|---|---|---| | Metoclopramide | Strong (approved) | D2 antagonist, prokinetic + antiemetic | Tardive dyskinesia with long use | | Domperidone | Moderate (not FDA-approved in US) | D2 antagonist | QT prolongation | | Erythromycin | Moderate | Motilin agonist | Tachyphylaxis, QT | | Gastric electrical stimulation | Moderate | Neuromodulation | Surgical, device complications | | Dietary modification | Strong | Smaller meals, low fat/fiber | None | | Dronabinol | Weak (off-label) | CB1 agonist | Slows emptying, psychoactive | | Inhaled cannabis | Weak/anecdotal | CB1/CB2 agonism | Slows emptying, CHS risk, psychoactive |
Cannabis is not a substitute for prokinetics. It may be an adjunct for refractory nausea in patients who have exhausted standard options, ideally with gastroenterology supervision [1][9].
Risks specific to gastroparesis patients
- Cannabinoid hyperemesis syndrome (CHS). Chronic heavy cannabis use can cause cyclic vomiting that looks exactly like a gastroparesis flare. The only treatment is cannabis cessation. Patients with gastroparesis who use cannabis daily and develop worsening vomiting should be evaluated for CHS Strong evidence [4].
- Worsened gastric emptying. Demonstrated in human gastric emptying studies [2][3]. May reduce efficacy of oral medications that depend on normal absorption timing.
- Diabetic gastroparesis interactions. Erratic gastric emptying complicates insulin timing. Adding a drug that further slows emptying can destabilize glycemic control.
- Drug interactions. CBD inhibits CYP3A4 and CYP2C19 and can raise levels of co-administered drugs.
- Dehydration masking. Reducing the nausea sensation without fixing emptying can let patients under-recognize dehydration.
Again: this is not medical advice. If you have gastroparesis and are considering cannabis, or already using it, tell your gastroenterologist. The interaction with your other medications and with your underlying motility is the part that matters, and it requires individual assessment.
Sources
- Peer-reviewed Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L. Clinical guideline: management of gastroparesis. American Journal of Gastroenterology. 2013;108(1):18-37.
- Peer-reviewed Bateman DN. Delta-9-tetrahydrocannabinol and gastric emptying. British Journal of Clinical Pharmacology. 1983;15(6):749-751.
- Peer-reviewed Esfandyari T, Camilleri M, Busciglio I, Burton D, Baxter K, Zinsmeister AR. Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. American Journal of Physiology - Gastrointestinal and Liver Physiology. 2007;293(1):G137-G145.
- Peer-reviewed Sorensen CJ, DeSanto K, Borgelt L, Phillips KT, Monte AA. Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment—a Systematic Review. Journal of Medical Toxicology. 2017;13(1):71-87.
- Peer-reviewed Smith LA, Azariah F, Lavender VTC, Stoner NS, Bettiol S. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database of Systematic Reviews. 2015;(11):CD009464.
- Peer-reviewed Barbash B, Mehta D, Siddiqui MT, Chawla L, Dworkin B. Impact of cannabinoids on symptoms of refractory gastroparesis: a single-center experience. Cureus. 2019;11(12):e6430.
- Peer-reviewed Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. Journal of Pain and Symptom Management. 1995;10(2):89-97.
- Peer-reviewed Smith SH. Strain differences and the genetic basis of cannabis pharmacology. The chemotypic classification of cannabis is more useful than indica/sativa labels. Reviewed in: Piomelli D, Russo EB. The Cannabis sativa Versus Cannabis indica Debate: An Interview with Ethan Russo. Cannabis and Cannabinoid Research. 2016;1(1):44-46.
- Government National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Treatment for Gastroparesis. National Institutes of Health. ↗
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Cannabis and Nausea — What the evidence actually says about using cannabis and cannabinoids to treat nausea and...